AHA Late-Breaker: OCEAN(a)-DOSE – Reduction of Lipoprotein(a) With Small Interfering RNA

<p>Although lipoprotein(a) is believed to play a causal role in atherogenesis, there are no approved therapies to help lower it. The OCEAN(a) DOSE study examined a drug specifically designed to lower lipoprotein(a) through RNA interference.</p> <p>In this interview, Michelle L. O'Donoghue MD, MPH and Nanette Kass Wenger MD, MACC discuss AHA Late-Breaker: OCEAN(a)-DOSE – Reduction of Lipoprotein(a) With Small Interfering RNA.</p> <p><a href= "https://itunes.apple.com/us/podcast/eagles-eye-view-your-weekly-cv-update-from-acc-org/id1274635046"> Subscribe on Apple</a> Podcasts | <a href= "https://play.google.com/music/listen#/ps/I6dtkumvaipematzgzmbph2koiq"> Subscribe on Google Play</a> | <a href= "http://www.acc.org/education-and-meetings/products-and-resources/accel-audio"> Subscribe to ACCEL</a></p>